BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib

Podobne knjige/članki

• Transposon-mediated generation of BCR-ABL1-expressing transgenic cell lines for unbiased sensitivity testing of tyrosine kinase inhibitors
  od: Byrgazov, Konstantin, et al.
  Izdano: (2016)
• Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)
  od: Mian, Afsar Ali, et al.
  Izdano: (2021)
• Is there something wrong in paradise? Christian beliefs and the safety of novel BCR/ABL1 inhibitors
  od: Valent, Peter
  Izdano: (2011)
• Bcr-Abl: one kinase, two isoforms, two diseases
  od: Reckel, Sina, et al.
  Izdano: (2017)
• Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients
  od: Deininger, Michael W., et al.
  Izdano: (2016)